87 related articles for article (PubMed ID: 18632723)
1. A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer.
Doebele RC; Conkling P; Traynor AM; Otterson GA; Zhao Y; Wind S; Stopfer P; Kaiser R; Camidge DR
Ann Oncol; 2012 Aug; 23(8):2094-2102. PubMed ID: 22345119
[TBL] [Abstract][Full Text] [Related]
2. Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer.
Goto Y; Sekine I; Tanioka M; Shibata T; Tanai C; Asahina H; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Kikkawa H; Ohki E; Tamura T
Invest New Drugs; 2012 Aug; 30(4):1548-56. PubMed ID: 21748299
[TBL] [Abstract][Full Text] [Related]
3. The Purinergic Landscape of Non-Small Cell Lung Cancer.
Janho Dit Hreich S; Benzaquen J; Hofman P; Vouret-Craviari V
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454832
[TBL] [Abstract][Full Text] [Related]
4. FGF/FGFR-Dependent Molecular Mechanisms Underlying Anti-Cancer Drug Resistance.
Szymczyk J; Sluzalska KD; Materla I; Opalinski L; Otlewski J; Zakrzewska M
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830951
[TBL] [Abstract][Full Text] [Related]
5. Learning from Yeast about Mitochondrial Carriers.
Mentel M; Chovančíková P; Zeman I; Polčic P
Microorganisms; 2021 Sep; 9(10):. PubMed ID: 34683364
[TBL] [Abstract][Full Text] [Related]
6. Survival-associated alternative splicing signatures in non-small cell lung cancer.
Zhao D; Zhang C; Jiang M; Wang Y; Liang Y; Wang L; Qin K; Rehman FU; Zhang X
Aging (Albany NY); 2020 Apr; 12(7):5878-5893. PubMed ID: 32282333
[TBL] [Abstract][Full Text] [Related]
7. 100 Years of Suramin.
Wiedemar N; Hauser DA; Mäser P
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844000
[TBL] [Abstract][Full Text] [Related]
8. Dual Tumor Suppressor and Tumor Promoter Action of Sirtuins in Determining Malignant Phenotype.
Carafa V; Altucci L; Nebbioso A
Front Pharmacol; 2019; 10():38. PubMed ID: 30761005
[TBL] [Abstract][Full Text] [Related]
9. Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.
Buqué A; Bloy N; Aranda F; Cremer I; Eggermont A; Fridman WH; Fucikova J; Galon J; Spisek R; Tartour E; Zitvogel L; Kroemer G; Galluzzi L
Oncoimmunology; 2016 Jun; 5(6):e1149674. PubMed ID: 27471617
[TBL] [Abstract][Full Text] [Related]
10. Purinergic receptors as potential therapeutic targets in Alzheimer's disease.
Woods LT; Ajit D; Camden JM; Erb L; Weisman GA
Neuropharmacology; 2016 May; 104():169-79. PubMed ID: 26519903
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics of telomerase inhibition and telomere shortening by noncytotoxic suramin.
Gan Y; Lu J; Yeung BZ; Cottage CT; Wientjes MG; Au JL
AAPS J; 2015 Jan; 17(1):268-76. PubMed ID: 25425294
[TBL] [Abstract][Full Text] [Related]
12. A combination treatment with DNA methyltransferase inhibitors and suramin decreases invasiveness of breast cancer cells.
Borges S; Döppler HR; Storz P
Breast Cancer Res Treat; 2014 Feb; 144(1):79-91. PubMed ID: 24510012
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes.
Lustberg MB; Pant S; Ruppert AS; Shen T; Wei Y; Chen L; Brenner L; Shiels D; Jensen RR; Berger M; Mrozek E; Ramaswamy B; Grever M; Au JL; Wientjes MG; Shapiro CL
Cancer Chemother Pharmacol; 2012 Jul; 70(1):49-56. PubMed ID: 22729159
[TBL] [Abstract][Full Text] [Related]
14. Bladder tissue pharmacokinetics of intravesical mitomycin C and suramin in dogs.
Hu L; Wientjes MG; Li J; Au JL
AAPS J; 2010 Dec; 12(4):586-91. PubMed ID: 20625863
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer.
Lam ET; Au JL; Otterson GA; Guillaume Wientjes M; Chen L; Shen T; Wei Y; Li X; Bekaii-Saab T; Murgo AJ; Jensen RR; Grever M; Villalona-Calero MA
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1019-29. PubMed ID: 20107799
[TBL] [Abstract][Full Text] [Related]
16. Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study.
Villalona-Calero MA; Otterson GA; Wientjes MG; Weber F; Bekaii-Saab T; Young D; Murgo AJ; Jensen R; Yeh TK; Wei Y; Zhang Y; Eng C; Grever M; Au JL
Ann Oncol; 2008 Nov; 19(11):1903-9. PubMed ID: 18632723
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer.
Villalona-Calero MA; Wientjes MG; Otterson GA; Kanter S; Young D; Murgo AJ; Fischer B; DeHoff C; Chen D; Yeh TK; Song S; Grever M; Au JL
Clin Cancer Res; 2003 Aug; 9(9):3303-11. PubMed ID: 12960116
[TBL] [Abstract][Full Text] [Related]
18. A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer.
Blumenschein GR; Kabbinavar F; Menon H; Mok TSK; Stephenson J; Beck JT; Lakshmaiah K; Reckamp K; Hei YJ; Kracht K; Sun YN; Sikorski R; Schwartzberg L;
Ann Oncol; 2011 Sep; 22(9):2057-2067. PubMed ID: 21321086
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
